GLP-1 Maintenance Programs After Weight Loss: 5 Safe Paths to Keep It Off (2026)
Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers. We may earn a commission if you sign up through our links — this does not affect our rankings or analysis.
The short answer (read this first)
The best GLP-1 maintenance programs after weight loss all have four things in common: real clinician oversight, a written dose plan, a clear “if-this-then-that” plan for regain, and a price you can afford long-term.
For most people, the decision comes down to five paths: stay on your effective dose, step down to the lowest dose that holds you, stretch your doses out under clinician guidance, switch to a daily oral GLP-1, or stop with a written fallback plan.
- FDA-approved medication (Wegovy, Zepbound, or Foundayo)? Start with Ro for insurance + prior-auth help, then compare Sesame Care for visible brand-name cash-pay pricing.
- Cash-pay compounded? Eden publishes the same price at every dose — which matters more in maintenance than at any other phase.
- If you stop cold turkey, the STEP 1 extension trial data shows ~two-thirds of lost weight regained within a year. How you transition matters more than whether you transition.
Quick disqualifier: If you have a personal or family history of medullary thyroid cancer or MEN 2, are pregnant or planning to be, have active pancreatitis or severe gastroparesis, or have an active eating disorder — this guide isn’t for you. Talk to an in-person specialist instead.
What we actually verified
We checked the things that change. Before this page went live, we verified:
- Pricing pages for Ro, Sesame Care, Eden, Yucca Health, Enhance MD, MEDVi, and Hims/Hers (May 2026)
- Foundayo availability and dosing on the DailyMed Foundayo label, Ro's product page, and Sesame Care's branded formulary
- FDA label language for Wegovy (Novo Nordisk prescribing info) and Zepbound (Lilly prescribing info)
- The ATTAIN-MAINTAIN trial data against Eli Lilly's December 18, 2025 investor release and the Nature Medicine peer-reviewed publication
- STEP 1 extension regain data (Wilding et al., Diabetes, Obesity and Metabolism, 2022)
- SURMOUNT-4 tirzepatide withdrawal data (Aronne et al., JAMA, December 2023)
- FDA warning letters including the February 20, 2026 letter to MEDVi (#721455) and the March 2026 wave of 30+ similar letters
- FDA's April 30, 2026 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list (public comments open through June 29, 2026)
- 2026 systematic review on regain after stopping weight-loss medications (PMC, 2026)
A quick map: which lane are you actually in?
| If this sounds like you… | Start here | Why |
|---|---|---|
| "I want FDA-approved medication or insurance help" | Ro (then compare Sesame Care) | Best fit for brand-name, insurance, and prior-auth questions |
| "I want visible brand-name cash-pay prices" | Sesame Care | Transparent pricing by product and dose |
| "I'm paying cash and OK with compounded — I just want simple pricing" | Eden (flat-rate compounded) | Same price at every dose — biggest math win in maintenance |
| "I'm still losing weight even though I hit my goal" | Talk to your prescriber first | Maintenance should stabilize you, not push you below goal |
| "I want to stop completely" | The stop-with-fallback plan | Stopping should be planned, not casual |
| "I have no idea which path is mine" | Take our 60-second matching quiz | We'll show you the lane that fits |
What is a “GLP-1 maintenance program after weight loss”?
A GLP-1 maintenance program is the plan you follow after you’ve hit (or are close to) your goal weight to keep that weight stable — usually with a lower dose, a longer dose interval, a switch to a different medication, or a structured taper. A real maintenance program is not just “the same subscription, smaller dose.” It includes a written dose plan, weight-trend tracking, a food-noise check-in, and a clear trigger for what happens if weight starts coming back.
What a good maintenance program actually includes
If your current program is missing more than two of these, it’s not really a maintenance program — it’s a refill auto-pay.
- A written dose plan — what dose, how often, for how long
- A weight range — your "stay here" zone (not a single number)
- A regain trigger — at what weight do you call the provider
- Food-noise check-ins — because food noise often comes back before the scale moves
- A nutrition and resistance-training plan to protect muscle mass
- Cancellation/refund terms in writing — read these before you enroll, not after
- A switching pathway — can you go up, down, or sideways without re-onboarding
- A clinician you can actually reach — messaging or visits within 48 hours
Do you really have to stay on a GLP-1 forever?
Not necessarily — but stopping abruptly is the path with the worst published outcomes. The big trials (STEP 1 for semaglutide and SURMOUNT-4 for tirzepatide) both showed substantial weight regain within a year of stopping, and a 2026 systematic review of 37 studies estimated average regain of about 0.4 kg per month — projected to return people to baseline weight within roughly 1.7 years.
What the maintenance trials actually showed
| Trial | What was tested | Result |
|---|---|---|
| STEP 1 extension (Wilding et al., 2022) | Stopped semaglutide 2.4 mg + lifestyle after 68 weeks | Participants lost 17.3% of body weight, then regained 11.6 percentage points within one year — about two-thirds of the loss |
| STEP 4 (Rubino et al., 2021) | Continued semaglutide vs. switched to placebo at week 20 | Continued group lost an additional 7.9%; placebo group gained 6.9% — a 14.8% difference |
| SURMOUNT-4 (Aronne et al., 2023) | Stopped tirzepatide MTD after 36 weeks vs. continued | Stopped group regained a mean 14% body weight in 52 weeks; 82% regained at least 25% of their prior loss |
| 2026 systematic review (PMC, 37 studies, 9,341 adults) | Pooled regain after stopping weight-loss meds | ~0.4 kg/month average regain; projected return to baseline by ~1.7 years |
The honest takeaway: this isn’t about willpower. After major weight loss, your body fights to get the weight back. Hunger hormones rise. Resting metabolic rate drops. Food noise comes back. The medication was doing real biological work, and pulling it out without a plan undoes that work fast.
The real answer: Most people will benefit from staying on some form of GLP-1 long-term, but with the right structure, some people can step down or stop without losing everything. Which group you’re in depends on your weight history, your habits, your access to support, and your prescriber’s read on your situation.
The 5 maintenance paths (and which one fits you)
There are five evidence-supported paths to maintain weight loss after a GLP-1. Each one has different costs, risks, and provider fits — and the “right” path depends on your priorities, not a universal best answer.
Continue your current effective dose
Evidence strength: RCT withdrawal evidence (STEP 4, SURMOUNT-MAINTAIN design)
Best for: People whose dose is well tolerated, who can afford it, and who want the lowest-regain path.
STEP 4 showed people who continued semaglutide kept losing or held steady; people switched to placebo gained back weight fast. SURMOUNT-MAINTAIN is currently testing the same idea with tirzepatide.
The catch: Highest ongoing cost, and side effects don't usually disappear on their own.
Provider fit: Any responsibly-run program. Ro if you want FDA-approved + insurance. Eden if you're cash-pay and want predictable pricing.
Step down to the lowest effective dose
Evidence strength: Real-world clinical practice; SURMOUNT-MAINTAIN trial of labeled lower doses still in progress
Best for: People who tolerate the med but want lower cost or fewer side effects.
Your prescriber lowers your dose one step at a time (every 4 weeks is typical) while watching your weight, hunger, and food noise. If weight starts to creep back, you go back up.
The catch: Below the FDA's labeled maintenance dose, the trial evidence thins out. Some providers raise prices when you lower your dose. Read the cancellation terms.
Provider fit: Eden is the standout here — the price stays the same whether you're on 0.5 mg or 2.4 mg of semaglutide. Most other providers tier pricing by dose.
Stretch your doses out under clinician guidance
Evidence strength: Real-world clinical practice; limited published RCT evidence on extended-interval dosing
Best for: People on pens (where dose adjustment is harder) or people who want to extend their supply.
Some clinicians move patients from weekly injections to every 10 days or every 2 weeks. This is not FDA-labeled dosing — it's a real-world practice that some obesity-medicine clinicians use and others don't.
The catch: The evidence is still emerging. Don't do this on your own. If blood sugar is affected (especially if you take other diabetes medications), spacing doses can be risky.
Provider fit: Any program where you can reliably reach a clinician for dose adjustments. Avoid providers where you mostly interact with an app and rarely with a person.
Switch from a weekly injection to a daily oral GLP-1
Evidence strength: Phase 3 RCT data (ATTAIN-MAINTAIN); FDA-labeled dosing for Foundayo
Best for: People sick of weekly injections, who want simpler travel/storage, or who want a path with newer trial data.
Foundayo (orforglipron) is an FDA-approved once-daily oral GLP-1 receptor agonist for chronic weight management. The December 2025 ATTAIN-MAINTAIN trial — the first Phase 3 study of switching from injection to pill for maintenance — showed: people who switched from tirzepatide maintained ~75% of prior weight loss vs. 49% on placebo; people who switched from semaglutide maintained ~79% vs. 38% on placebo. People who switched from Wegovy to orforglipron regained on average just 0.9 kg.
The catch: Relatively new option. Long-term real-world data is still building.
Provider fit: Ro publicly lists Foundayo and includes insurance support. Sesame Care also lists Foundayo with cash-pay pricing by dose. No compounded provider can carry Foundayo — it's a brand-name FDA-approved drug.
See Ro’s GLP-1 maintenance options — including FoundayoStop with a written fallback plan
Evidence strength: Editorial framework backed by real-world programs (e.g., Omada-style behavioral support models)
Best for: People at goal weight, metabolically healthy, with strong daily habits, and ready to come off — with a real plan if regain starts.
A "fallback plan" stop is different from a cold-turkey stop. You taper slowly (one dose step every 4 weeks). You track weight weekly, food noise daily, hunger daily. You pre-commit to a regain threshold — say, 5 pounds above your maintenance range — that triggers a restart conversation. You build the lifestyle floor (protein, resistance training, sleep, behavioral support) before you reduce, not after.
The catch: This is the path with the highest regain risk in the trial literature, but the best emotional outcome when it works. It also requires the most discipline.
Provider fit: Any program with strong messaging access and a clinician comfortable supporting a taper. Programs like Form Health and Calibrate are explicitly built around this.
GLP-1 maintenance programs compared: the verified fit matrix
The best GLP-1 maintenance program after weight loss depends on whether you need FDA-approved medication, want flat-rate compounded pricing, prefer a daily pill, or need lab-guided care. Below is our verified comparison of the six programs that earned their spot as of May 2026 — including the regulatory caveats you need to know.
| Provider | Best maintenance fit | Maintenance-phase price | FDA-approved access | Flat-rate at lower doses? | Insurance / HSA / FSA | FDA warning letter? |
|---|---|---|---|---|---|---|
| Ro | FDA-approved, insurance route, Foundayo | $39 first month, $149/mo or $74/mo annual prepay + medication | ✅ Foundayo, Wegovy pill, pen, Zepbound pen, KwikPen | Membership-based, not dose-tied | ✅ Insurance concierge + free Coverage Checker; HSA/FSA | None found |
| Sesame Care | FDA-approved brand cash-pay, provider choice | From $59/mo (annual sub) + medication; Foundayo $149–$349/mo by dose; Wegovy pill $149–$299/mo by dose | ✅ Wegovy, Zepbound, Ozempic, Mounjaro, Foundayo | Medication priced by dose | HSA/FSA accepted | None found |
| Eden | Cash-pay compounded, flat-rate | $149 first month; $249/mo flat at every dose; prepaid plans may be lower — verify at checkout | Lists Wegovy, Zepbound (brand prices vary) | ✅ Same price at every dose | HSA/FSA accepted; no insurance | None found |
| Enhance MD | Lab-guided cash-pay maintenance | Sema $49 first month then $212/mo; tirz $99 first month then $280/mo; labs every 6 months | Compounded primary | ✅ Same price at all doses | HSA/FSA accepted | None found |
| Yucca Health | Low-friction self-pay, BNPL | From $146/mo (new patient, 6-mo plan); Klarna, Affirm, Afterpay | Compounded primary | Plan-based pricing | HSA/FSA limited; BNPL available | None found |
| MEDVi | See honest section below | Sema injections $179 first month, up to $299 ongoing; sema tablets up to $369; tirz $279–$399 | Limited brand path | Tiered | HSA/FSA accepted; no insurance | ⚠️ FDA warning letter Feb 20, 2026 (#721455) |
Provider deep-dives
Ro — best for FDA-approved maintenance, Foundayo, and insurance help
If your priority is FDA-approved medication and someone who can help you navigate insurance or prior authorization, Ro is the strongest starting point in this guide. They publicly list Foundayo, Wegovy pill, Wegovy pen, Zepbound pen, and Zepbound KwikPen, and they match LillyDirect, NovoCare, and TrumpRx pricing on the medication itself. Membership: $39 first month, then $149/month, or as low as $74/month with annual plan paid upfront — medication cost is separate.
What that buys you:
- A free GLP-1 Insurance Coverage Checker — a real benefits check in minutes
- An insurance concierge that files prior-authorization paperwork on your behalf
- Access to every FDA-approved weight-loss GLP-1 on one platform
- Foundayo access — Ro lists Foundayo on its pricing page, making it a clean operational path to the FDA-approved oral GLP-1
Honest tradeoff: Ro does not have the cheapest sticker price if you’re paying fully cash and don’t need brand-name medication. If you’re cash-pay and OK with compounded, Eden or Yucca may be cheaper. But neither carries Foundayo, neither offers insurance help, and neither will handle a prior authorization for you.
Pricing verified from Ro’s public pricing and insurance pages, May 2026.
See Ro’s GLP-1 maintenance options — including FoundayoSesame Care — best for visible brand-name cash pricing (including Foundayo by dose)
If you want FDA-approved medication but you’re paying cash and want to see the price for each medication and dose up front, Sesame Care is the cleanest option we verified. Program runs from $59/month with annual subscription; medication is priced separately and listed by product.
| Medication | Cash-pay price |
|---|---|
| Foundayo | $149/mo (0.8 mg) · $199/mo (2.5 mg) · $299/mo (5.5 mg, 9 mg) · $349/mo (14.5 mg, 17.2 mg) |
| Wegovy pill | $149/mo at lower doses; up to $299/mo at 9 mg and 25 mg |
| Wegovy pen | $199/mo first two months, then $349/mo |
| Zepbound KwikPen | $299/mo at lowest dose, scaling to $698/mo at higher doses |
| Also available | Ozempic, Mounjaro, Saxenda |
Pricing verified from Sesame Care’s public weight loss program page, May 2026.
Honest tradeoff: Sesame Care does not include the same insurance concierge that Ro does. If your priority is insurance navigation and prior-auth paperwork, Ro is the stronger fit.
Compare Sesame Care’s brand-name GLP-1 pricesEden — best for flat-rate compounded maintenance
If your prescriber says a compounded GLP-1 is appropriate and you’re paying cash, Eden is the program with the simplest math in maintenance. Verified compounded semaglutide pricing: $149 first month, then $249/month ongoing — same price at every dose. Verify exact month-to-month and prepaid pricing at checkout before enrolling.
Why flat-rate matters more in maintenance than any other phase: With most providers, lowering your dose doesn’t lower your bill — and raising your dose back up surprises you. Eden’s flat-rate model means stepping down to maintenance doesn’t penalize you and stepping back up doesn’t surprise you. That’s the right structure for the long-term phase you’re entering.
- Lists both compounded and brand-name medications (Wegovy, Zepbound) on the same platform
- Month-to-month — no contract
- HSA/FSA accepted; no insurance
- 24/7 messaging with the care team
Honest tradeoff: Eden does not carry Foundayo, the FDA-approved daily oral pill. If you specifically want to switch from a weekly injection to an FDA-approved oral medication, Ro is the right answer.
Compounded reminder: Compounded medications are not FDA-approved as finished products. Verify the named pharmacy, license status, formulation, and whether the pharmacy operates under 503A or 503B requirements before enrolling.
See Eden’s same-price-at-every-dose planVerify current plan pricing, state availability, pharmacy source, and cancellation terms before enrolling.
Enhance MD — best for lab-guided maintenance with monitoring
If you want a more clinical experience — including metabolic lab work every 6 months and a dose-stable price structure — Enhance MD’s model is a strong fit.
Core semaglutide
$49 first month, then $212/month
Same pricing at all doses. Free shipping, provider support, metabolic lab testing every 6 months.
Advanced tirzepatide
$99 first month, then $280/month
Same pricing at all doses. Free shipping, provider support, metabolic lab testing every 6 months.
Note: Enhance MD is not an affiliate of Weight Loss Provider Guide. We include them because they fill a genuine reader need for lab-monitored cash-pay maintenance. Compounded medications only; not FDA-approved as finished products.
Yucca Health — best for low-friction, value-first, BNPL
If your biggest concern is keeping the monthly cost down and you want a low-friction self-pay program with installment options, Yucca Health is the cleanest value pick we verified. Public site shows from $146/month for new patients on a semaglutide 6-month plan, and they accept Klarna, Affirm, and Afterpay at checkout.
- Cash-pay, comfortable with compounded, want the lowest published monthly price
- Want flexible payment options (BNPL)
- OK doing more of the verification yourself
Honest tradeoff: Yucca does not offer the same level of monitoring or labs that Enhance MD or Ro do. Verify during intake whether your plan includes live visits, asynchronous review, messaging, or scheduled clinician check-ins.
Check Yucca Health’s self-pay maintenance plansMEDVi — read this before enrolling
The FDA warning letter. On , the FDA issued warning letter #721455 to MEDVi, LLC, citing misbranding violations — specifically language falsely implying FDA approval of compounded products, and “same active ingredient as Wegovy® and Ozempic®” claims the FDA said falsely implied FDA approval or evaluation.
The wider context. MEDVi was not alone. In March 2026, the FDA issued warning letters to more than 30 telehealth companies for similar marketing violations.
The cancellation policy. MEDVi’s published policy requires cancellation requests at least 72 hours before your next billing date. Except for medical disqualification, no refund is issued upon cancellation. Read the full terms before entering payment information.
Pricing (verify at checkout): Compounded sema injections from $179 first month up to $299 ongoing; sema tablets up to $369; tirzepatide $279–$399.
Better-fit alternatives: Yucca Health ($146/mo) or Eden ($249/mo flat) for the low cash-pay price. Foundayo via Ro for the FDA-approved oral option.
Already on MEDVi and thinking about switching? See the full switching checklist →
What the FDA-approved maintenance doses actually are
The word “maintenance” gets thrown around loosely on telehealth sites, and the FDA-labeled meaning is specific. If a telehealth provider tells you that a sub-label dose is your “maintenance dose,” that’s real-world clinical practice — not an FDA-labeled maintenance dose. Both can be valid in the right hands. But you should know the difference.
| Medication | FDA-approved dosing | Notes |
|---|---|---|
| Wegovy injection (semaglutide 2.4 mg) | 1.7 mg or 2.4 mg once weekly; 2.4 mg is the recommended maintenance dose | Titration doses (0.25 mg, 0.5 mg, 1.0 mg) are not maintenance doses |
| Wegovy oral tablet (semaglutide pill, 2026) | 25 mg once daily as labeled maintenance | Verify current product availability and label |
| Zepbound (tirzepatide) | 5 mg, 10 mg, or 15 mg once weekly | 2.5 mg is initiation only — not an approved maintenance dose |
| Foundayo (orforglipron, oral) | Start 0.8 mg once daily; after ≥30 days → 2.5 mg; after ≥30 days → 5.5 mg; then may increase to 9 mg, 14.5 mg, or 17.2 mg once daily. Maximum: 17.2 mg once daily. | DailyMed label, verified May 2026 |
What it actually costs to stay on a GLP-1 for maintenance (True Year Cost)
The “True Year Cost” — what you’ll actually spend over 12 months — is what matters, not the introductory price. Below are worked examples using verified prices (May 2026). Medication cost is separate from membership unless noted.
| Path | Year 1 cost (membership/program only) | Medication cost note |
|---|---|---|
| Ro (annual prepay) | ~$888 ($74/mo × 12) | Brand medication priced separately; insurance may reduce |
| Ro (monthly) | ~$1,678 ($39 + $149 × 11) | Brand medication priced separately |
| Sesame Care (annual sub) | ~$708 ($59/mo × 12) | Brand medication priced by product and dose |
| Eden (compounded sema, month-to-month) | ~$2,888 ($149 + $249 × 11) | Medication bundled |
| Enhance MD (compounded sema) | ~$2,381 ($49 + $212 × 11) | Medication and labs bundled |
| Enhance MD (compounded tirz) | ~$3,179 ($99 + $280 × 11) | Medication and labs bundled |
| Yucca Health (6-mo plan starting price) | From ~$1,752 ($146 × 12 advertised entry) | Verify ongoing price after intro term |
| MEDVi (compounded sema injections) | ~$3,469 ($179 + $299 × 11) | Verify current pricing at checkout |
Why “starter price” is misleading: A $39 first month or $99 introductory offer tells you very little about year two. The maintenance phase is where the real long-term cost lives. Always check the ongoing monthly price, the cancellation terms, and what happens when your dose changes. See our GLP-1 providers with flat-rate pricing comparison.
How do you switch GLP-1 providers once you’re on maintenance?
Switching providers during maintenance can absolutely work — but the order matters. Document first, cancel last. Going without that documentation can mean your new clinician resets you to a starter dose, which is the last thing you want when you’re trying to hold maintenance.
The order that works:
- Pick the new provider first (use the fit matrix above, or take our quiz)
- Save your current records: medication, exact dose, last dose date, screenshots of your label, pharmacy name, insurance approval/denial letters, recent weight trend
- Enroll with the new provider and complete intake before canceling the old one
- Get the new prescription written and in transit
- Then cancel the old provider (mind the 72-hour cancellation windows some programs have)
- Bridge the gap if needed — even a 1-2 week refill gap can affect appetite return
Can you stretch GLP-1 doses out farther apart to save money?
Yes, some clinicians work with patients to extend the time between doses — for example, moving from weekly to every 10 or 14 days. This is not FDA-labeled dosing, and it should always be a clinician’s call, not a do-it-yourself decision.
The case for stretching
- If you're on a pen, you can't easily lower the per-injection dose — spacing is the only adjustment available
- Can reduce monthly medication cost without adding new side effects
- For some patients with stable weight, it works
The case for caution
- No large RCT specifically on extended-interval dosing for maintenance
- If you take other diabetes medications, spacing can increase the risk of low blood sugar
- DIY stretching (without your prescriber knowing) makes side-effect tracking harder
Don’t do this on your own. Stretching your dose interval without telling your prescriber is the same as changing your medication without telling them. Bring it up at your next visit — most clinicians have a clear opinion on whether it fits your situation.
What happens if you stop your GLP-1 completely?
If you stop a GLP-1 cold turkey, the published evidence says appetite and food noise often return within weeks, weight regain typically starts within 2-4 months, and over a year you can lose most of the cardiometabolic benefits — including improvements in blood pressure, blood sugar, and lipid markers.
Cold turkey timeline
- Weeks 1-4: appetite starts increasing; food noise returns
- Months 2-4: weight trend creeps up 3-10 lb
- Months 4-12: old cues and habits become harder to manage
- Year 2: trial data projects return to roughly baseline weight if no support is added
Stop with fallback plan
- Confirm your prescriber is on board
- Pick a dose-reduction schedule — one step down every 4 weeks
- Pre-commit to a regain threshold (e.g., 5 lb above maintenance range triggers restart)
- Build the lifestyle floor before first reduction
- Track weekly: weight, food-noise score, hunger score, protein, training
- Schedule check-ins at weeks 4, 8, and 12 after each dose change
- Have an off-ramp — know how you'd restart if needed
Exercise is not optional in maintenance. A 2024 published study showed that adding supervised exercise to obesity pharmacotherapy and continuing it after stopping the medication helped people maintain body weight and body composition for a year — while regain occurred in the medication-only group. Strength training and protein matter more than they sound.
What if food noise comes back?
Food noise returning — constant, intrusive thoughts about food — is one of the clearest early warning signs that your maintenance plan needs adjustment. Don’t wait for the scale to move. Track food noise daily on a 1-10 scale and call your prescriber if it stays elevated for more than a week.
A simple food-noise scale
| Score | What it feels like |
|---|---|
| 1–3 | Quiet. Food fits into your life without effort. |
| 4–6 | Noticeable but manageable. Some cravings; no bargaining. |
| 7–8 | Daily friction. You're negotiating with yourself often. |
| 9–10 | Intrusive. You feel like you're losing the progress you made. |
When to call your prescriber
- Food-noise score is 7+ for 7 days in a row
- Weight trend is up 3–5 pounds from your maintenance range
- Hunger is interfering with sleep or daily function
- Loss-of-control eating is returning
- Side effects are preventing adequate nutrition
What questions to ask your prescriber before changing your plan
Save your prescriber’s answers in writing or in a note on your phone. This becomes the document you’d hand to a new clinician if you ever switch providers.
- Am I officially in maintenance, or should I keep losing first?
- What weight range should I maintain (not just a single number)?
- What dose are we targeting for maintenance?
- Should I step down, stay, stretch out, switch, or stop?
- What symptoms or labs would make a dose change unsafe?
- What food-noise level should trigger a call to you?
- What weight gain over what timeframe should trigger a dose change?
- Should I monitor labs? Which ones, and how often?
- Am I at any risk of low blood sugar based on my other medications?
- What should I do if I miss a dose?
- What happens if I can't afford next month's medication?
- Can you document continuation-of-care if my insurance asks?
- If I want to switch providers, what records do I need?
- What should I do if side effects get worse instead of better?
- What's the exact fallback plan if I start regaining?
A 30-day GLP-1 maintenance tracker (free to copy)
This is an editorial tracking tool, not a diagnostic tool.
| Metric | How often | Why it matters |
|---|---|---|
| Weight (7-day average) | Daily, average weekly | Smooths out noise; shows real trend |
| Food noise (1-10) | Daily | Earliest warning sign of regain |
| Hunger (1-10) | Daily | Helps your prescriber judge dose fit |
| Protein intake | Daily | Supports satiety and lean mass |
| Resistance training | Weekly | Preserves muscle during maintenance |
| Waist measurement | Monthly | Separates fat regain from scale noise |
| Side effects | As they happen | Prevents overtreatment |
| Cost / refill stress | Monthly | Predicts when you'll be tempted to stop |
What if insurance stops covering your GLP-1 after you lost weight?
If insurance stops covering your GLP-1 because you no longer meet the plan’s BMI threshold, don’t cancel care immediately. Get the denial reason in writing and compare your options — usually in this order:
- Get the denial in writing — you need the exact reason
- Ask your prescriber for continuation-of-care documentation — updated weight, BMI history, comorbidities, and treatment response notes
- Use Ro's free GLP-1 Insurance Coverage Checker to verify what's still available under your plan
- Compare Sesame Care or manufacturer cash-pay (LillyDirect, NovoCare, TrumpRx) for brand-name options
- Then — only if appropriate — compare cash-pay compounded with the verification checklist below
The trap to avoid: Letting your refill gap force an unplanned stop. A refill gap can quickly turn into an unplanned stop, so plan the transition before you run out.
What to verify before choosing a compounded maintenance program
The 2026 regulatory reality
- The FDA declared the semaglutide injection shortage resolved on February 21, 2025 and the tirzepatide injection shortage resolved on December 19, 2024
- The FDA's compounding enforcement-discretion timelines tied to those shortages ended in 2025
- In March 2026, the FDA issued warning letters to 30+ telehealth companies for misbranding compounded GLP-1 marketing
- On April 1, 2026, FDA clarified that a compounded product combining semaglutide with vitamin B12 may still be considered "essentially a copy" of an FDA-approved drug unless a prescriber documents a patient-specific significant difference
- On April 30, 2026, FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. Public comments open through June 29, 2026 — this is proposed, not final
The verification checklist
- Name of the prescribing clinician
- Name and license number of the pharmacy (503A pharmacy or 503B outsourcing facility?)
- State licensing
- Exact formulation (semaglutide alone, semaglutide + B12, etc.)
- Storage requirements and beyond-use date
- Refill process and how dose changes are handled
- Cancellation policy in writing
- Refund policy in writing
- Whether the provider has any active FDA warning letters
- Whether the provider's marketing avoids "same as brand" or "FDA-approved" language
- Screenshot the relevant terms and pricing before you pay
- Date-stamp your verification
If any of these can’t be answered clearly, that’s a yellow flag. Multiple unanswered? Walk away.
A real-reader testimonial (and how we picked it)
“Lowered me to a maintenance dose for safety reasons.”
We include this because it captures something real about how maintenance is supposed to work: a clinician noticing that the active-loss dose isn’t right for the next phase, and stepping the dose down deliberately. Individual experiences vary; testimonials do not establish safety or effectiveness.
Dr. Louis Aronne, lead author of SURMOUNT-4, framed it this way: “The SURMOUNT-4 trial results emphasize the need to continue pharmacotherapy to prevent weight regain and ensure the maintenance of weight reduction and its associated cardiometabolic benefits.”
Honest tradeoffs and who shouldn’t use these maintenance programs
Telehealth GLP-1 maintenance programs aren’t right for everyone. Route to in-person specialist care if any of these apply to you.
Do not choose a telehealth maintenance program if you have:
- A personal or family history of medullary thyroid carcinoma or MEN 2 — contraindicated
- Active pancreatitis, severe gastroparesis, or significant gallbladder disease
- Pregnancy, planned pregnancy within 2 months, or breastfeeding
- Bariatric surgery follow-up without your bariatric team's coordination
- Type 1 diabetes — different prescribing context
- Significant kidney or liver disease
- No primary care provider visit in 2+ years
- An active eating disorder (anorexia, bulimia)
If any of these apply, don’t use a provider link from this page. Contact an in-person clinician instead.
Frequently asked questions about GLP-1 maintenance programs
What is the best GLP-1 maintenance program after weight loss?
The best program depends on your lane. For FDA-approved medication and insurance help, Ro is the strongest starting point. For transparent brand-name cash-pay pricing (including Foundayo priced by dose), Sesame Care. For flat-rate compounded maintenance, Eden at $249/month flat at every dose. For lab-guided cash-pay care, Enhance MD. For lowest cash-pay price with BNPL, Yucca Health.
Do you have to stay on a GLP-1 forever to maintain weight loss?
Not necessarily, but the trial evidence shows substantial weight regain after stopping — about two-thirds of lost weight regained within a year in the STEP 1 extension trial. Real-world data with strong lifestyle support and a structured taper shows better outcomes. Most people benefit from staying on some form of GLP-1 long-term, but a structured taper can work for the right person.
What is the FDA-approved maintenance dose for Wegovy?
The FDA-approved maintenance doses for Wegovy injection are 1.7 mg or 2.4 mg once weekly, with 2.4 mg as the recommended maintenance dose for adult weight reduction. The titration doses (0.25 mg, 0.5 mg, 1.0 mg) are not FDA-labeled maintenance doses.
What is the FDA-approved maintenance dose for Zepbound?
The FDA-approved maintenance doses for Zepbound are 5 mg, 10 mg, or 15 mg once weekly for weight reduction and long-term weight maintenance. The 2.5 mg starting dose is for treatment initiation only and is not an approved maintenance dose.
What is the FDA-approved dosing for Foundayo?
Per the DailyMed label: start at 0.8 mg once daily; after at least 30 days, increase to 2.5 mg once daily; after at least 30 days, increase to 5.5 mg once daily. The dose may then increase to 9 mg, 14.5 mg, or 17.2 mg once daily based on response and tolerability. Maximum dose: 17.2 mg once daily.
Can I switch from Wegovy or Zepbound to a daily pill for maintenance?
Yes. The December 2025 ATTAIN-MAINTAIN trial showed patients who switched from Wegovy or Zepbound to oral orforglipron (Foundayo) for 52 weeks maintained roughly 75% (from tirzepatide) and 79% (from semaglutide) of their prior weight loss; placebo groups maintained only 49% and 38%. Ro publicly lists Foundayo and is a strong first look for the FDA-approved oral path; Sesame Care also lists Foundayo with cash-pay pricing by dose.
Can you take GLP-1 shots every 10 to 14 days for maintenance?
Some clinicians work with patients to space doses farther apart as a maintenance strategy, but this is not FDA-labeled dosing and the research is still emerging. It should always be a prescriber's decision, not a do-it-yourself adjustment — especially if you take other diabetes medications that affect blood sugar.
Is compounded GLP-1 still legal in 2026?
Compounded GLP-1s are not categorically illegal, but their legal status depends on whether the pharmacy and prescription meet 503A or 503B requirements and patient-specific need. In March 2026, the FDA issued warning letters to 30+ telehealth companies for misbranding compounded GLP-1 marketing. On April 30, 2026 the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. Compounded medications are not FDA-approved as finished products.
What if my insurance stops covering my GLP-1 because I lost weight?
Request the denial reason in writing, ask your prescriber for continuation-of-care documentation, and use Ro's free Insurance Coverage Checker to verify what your plan still covers. Compare FDA-approved cash-pay options (Sesame Care, LillyDirect, NovoCare) before switching to compounded — and don't let a refill gap force an unplanned stop.
What should I do if food noise comes back during maintenance?
Track food noise daily on a 1-10 scale. If it stays at 7 or above for a week, or if you are seeing 3-5 lb above your maintenance range, contact your prescriber. Food noise returning is an early warning sign that needs a clinical response, not a personal failure.
How we built this comparison (methodology)
We built this comparison to separate three things that get mixed up everywhere else: medical and regulatory facts (sourced from FDA labels, FDA enforcement pages, and peer-reviewed studies), verified commercial facts (sourced from provider websites and third-party review databases), and editorial recommendations (our judgment about which provider fits which reader best).
Source hierarchy:
- FDA labels and FDA.gov official guidance
- Peer-reviewed published trial data (STEP, SURMOUNT, ATTAIN-MAINTAIN, PMC systematic review)
- Provider websites and public pricing pages, verified May 2026
- FDA enforcement letters (FDA.gov Warning Letters database)
- Third-party review databases (ConsumerAffairs, BBB, Trustpilot) for verified-purchase service reviews
- Our editorial framework for provider ranking, which treats regulatory standing as a threshold criterion
Re-verification cadence: Pricing and provider availability are re-checked monthly. Regulatory status is re-checked on any FDA enforcement news. Trial data is updated when new peer-reviewed publications appear.
Ready to find your maintenance path?
This article is for informational purposes only and is not medical advice. GLP-1 medications require a prescription from a licensed clinician based on a clinical evaluation. We are an independent comparison resource — we don’t prescribe medication, we don’t determine eligibility, and our editorial recommendations are not a substitute for a conversation with a healthcare provider. Pricing and availability change frequently — verify before paying.
Compounded medications are not FDA-approved and the FDA cannot verify their quality, safety, or effectiveness before marketing. Wegovy® and Ozempic® are registered trademarks of Novo Nordisk A/S. Mounjaro®, Zepbound®, and Foundayo™ are trademarks of Eli Lilly and Company. Weight Loss Provider Guide is not affiliated with or endorsed by Novo Nordisk or Eli Lilly.
Article verified: . Next scheduled re-verification: June 23, 2026.
Last verified: